CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
ofatumumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01239394
NCT01239394Phase 2Completed
CompareCT.gov

Phase II Trial Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Massachusetts General Hospital·interventional·Posted Nov 11, 2010·Updated Oct 18, 2017

In Brief

A Phase 2 clinical trial evaluating ofatumumab for Follicular Lymphoma and 2 related conditions. Completed, enrolled 43 participants across 3 sites.

Detailed Summary

Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells. It is approved by the FDA for treatment of another B-cell cancer, chronic lymphocytic leukemia, and also has evidence of success in people who's B-cell lymphomas have relapsed after initial treatments. In this research study we are looking to see if ofatumumab is effective and safe in treating previously untreated B-cell NHL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, GlaxoSmithKline

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2010
Enrollment StartDec 1, 2010
Primary CompletionMar 1, 2013
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.6 years ago

Interventions

ofatumumabdrug

Weekly infusion for 8 weeks